Proteasome Inhibition with PS-341 (Bortezomib) in Lung Cancer Therapy

Primo N. Lara, Angela M. Davies, Philip C. Mack, Melinda M. Mortenson, Richard J. Bold, Paul H. Gumerlock, David R. Gandara

Research output: Contribution to journalArticle

36 Scopus citations

Abstract

PS-341 (bortezomib) represents a new class of therapeutics that targets the ubiquitin-proteasome pathway. It has broad-spectrum single-agent anticancer activity and can potentiate chemotherapy and radiation in preclinical models. Early phase clinical studies have shown tolerability and activity in multiple myeloma, lymphoma, prostate cancer, and lung cancers. By its mechanism of inhibiting protein degradation, PS-341 targets a wide range of pathways relevant to tumor progression and therapy resistance and can directly modulate expression of cyclins, p27Kip1, p53, nuclear factor-κB, Bcl-2, and Bax. PS-341 is currently in phase I/II clinical development in both non-small cell lung cancer and small cell lung cancer. This article will review the preclinical and clinical experience with PS-341 as it relates to lung cancer.

Original languageEnglish (US)
Pages (from-to)40-46
Number of pages7
JournalSeminars in Oncology
Volume31
Issue number1 SUPPL. 1
StatePublished - Feb 2004

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Proteasome Inhibition with PS-341 (Bortezomib) in Lung Cancer Therapy'. Together they form a unique fingerprint.

  • Cite this